The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive ...

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Sanofi (ENXTPA:SAN) received FDA approval for Dupixent as the first and only treatment for allergic fungal rhinosinusitis, expanding its use into a new indication. The company also appointed Belén ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for ...

Dupixent growth offsets Eylea declines; pipeline/Libtayo impact post-2026; monitor ROIC & SBC. Click for a REGN update.

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis. Approval in adults and children aged 6 years and older supp ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...